208 related articles for article (PubMed ID: 24114431)
1. SNPs within the GH-signaling pathway are associated with the early IGF1 response to GH replacement therapy in GHD adults.
Glad CA; Barbosa EJ; Filipsson Nyström H; Carlsson LM; Nilsson S; Nilsson AG; Svensson PA; Johannsson G
Eur J Endocrinol; 2014 Jan; 170(1):101-7. PubMed ID: 24114431
[TBL] [Abstract][Full Text] [Related]
2. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
3. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
4. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
Adetunji OR; MacFarlane IA; Javadpour M; Alfirevic A; Pirmohamed M; Blair JC
Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
[TBL] [Abstract][Full Text] [Related]
5. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
6. Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy.
Barbosa EJ; Glad CA; Nilsson AG; Filipsson Nyström H; Götherström G; Svensson PA; Vinotti I; Bengtsson BÅ; Nilsson S; Boguszewski CL; Johannsson G
Eur J Endocrinol; 2012 Sep; 167(3):353-62. PubMed ID: 22715478
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults.
Hartleb S; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Pfützner A; Kann PH; ;
Pharmacogenomics; 2011 Dec; 12(12):1653-61. PubMed ID: 22026923
[TBL] [Abstract][Full Text] [Related]
9. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients.
Mormando M; Chiloiro S; Bianchi A; Giampietro A; Angelini F; Tartaglione L; Nasto L; Milardi D; Formenti AM; Giustina A; De Marinis L
Clin Endocrinol (Oxf); 2016 Nov; 85(5):717-724. PubMed ID: 27437620
[TBL] [Abstract][Full Text] [Related]
11. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127
[TBL] [Abstract][Full Text] [Related]
12. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism.
Bianchi A; Giampietro A; Tartaglione L; Chiloiro S; Gentilella R; Bima C; Anile C; Olivi A; Pontecorvi A; De Marinis L
J Neuroendocrinol; 2019 Apr; 31(4):e12692. PubMed ID: 30712287
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
[TBL] [Abstract][Full Text] [Related]
14. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor.
Blum WF; Machinis K; Shavrikova EP; Keller A; Stobbe H; Pfaeffle RW; Amselem S
J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057
[TBL] [Abstract][Full Text] [Related]
15. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults.
van der Klaauw AA; van der Straaten T; Baak-Pablo R; Biermasz NR; Guchelaar HJ; Pereira AM; Smit JW; Romijn JA
J Clin Endocrinol Metab; 2008 Jul; 93(7):2828-34. PubMed ID: 18397980
[TBL] [Abstract][Full Text] [Related]
16. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
17. Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults.
Barbosa EJ; Koranyi J; Filipsson H; Bengtsson BA; Boguszewski CL; Johannsson G
Eur J Endocrinol; 2010 May; 162(5):869-78. PubMed ID: 20145045
[TBL] [Abstract][Full Text] [Related]
18. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.
Andujar-Plata P; Fernandez-Rodriguez E; Quinteiro C; Casanueva FF; Bernabeu I
Pituitary; 2015 Feb; 18(1):101-7. PubMed ID: 24710993
[TBL] [Abstract][Full Text] [Related]
19. The value of IGF1 estimation in adults with GH deficiency.
Mukherjee A; Shalet SM
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S33-9. PubMed ID: 19684059
[TBL] [Abstract][Full Text] [Related]
20. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
